Prostate Cancer Therapeutics Market Size Worth $12.0 Billion By 2025 Prostate Cancer Therapeutics Market | страница 2

tumor. Moreover, these players have various established brands such as Zytiga, Xtandi,
Eligard, Taxotere, Provenge, and Xofigo, which hold a strong position in the market.
Detailed Research Report available at:
http://www.grandviewresearch.com/industry-analysis/prostate-cancer-
therapeutics-market
In addition, there are many drugs in pipeline such as Tc-99m (Progenics), radium-223
dichloride (Xofigo, Bayer), and ODM-201 (Orion and Bayer), which are in their phase 3
studies and are expected to enter the market during the forecast period. In addition,
patents of many existing products are expiring during the forecast period. As a result,
generic products are anticipated to penetrate the market. All these factors together are
expected to propel growth.
In Canada, Prostate Cancer Foundation of Canada supports research, cure, and
prevention of prostate cancer through an online portal. This portal provides detailed
information regarding symptoms, diagnosis, and commercially available treatment
options. Such portals offer free access to people all around the world, which is resulting
in growth.
Further key findings from the study suggest:
•
•
•
•
•
The growing incidence of prostate cancer across the globe is expected to drive
growth
The market is segmented into hormonal therapy including Luteinizing Hormone
Releasing Hormone (LHRH) agonist, LHRH antagonist & antiandrogen;
chemotherapy; immunotherapy, and targeted therapy
Zytiga (Johnson & Johnson) is considered as a gold standard product for the
treatment of prostate cancer and holds a strong position. However, Xtandi (Astella,
Inc.) and Zytiga are competing with each other. The degree of competition is
projected to elevate during the forecast period. Thus, hormonal therapy holds the
largest share.
Provenge (Dendreon Corporation) is the only immunotherapy drug mainly used in
the treatment of advanced or metastasis of such cancerous cells
In addition, there are many promising immunotherapy drugs in the pipeline such
as INO-5150 SynCon and PROSTVAC (Bavarian Nordic), which are expected to
enter the market in the near future. Thus, this drug class is projected to be the
fastest growing segment.
Follow Us: